General information
  • Disease category Other Cancer (BASEC)
  • Recruitment status Unknown (BASEC/ICTRP)
  • Trial sites
    Bern, Zurich
    (BASEC)
  • Contact Prof. Dr. med. Matthias Guckenberger Matthias.Guckenberger@usz.ch (BASEC)
  • Data Source(s) BASEC: Import from 14.03.2025 ICTRP: N/A
  • Last update 14.03.2025 10:55
HumRes66588 | SNCTP000006325 | BASEC2024-02090

Comparison of the Toxicity of a Single Session versus Multiple Radiation Therapy Sessions for the Treatment of Metastases

  • Disease category Other Cancer (BASEC)
  • Recruitment status Unknown (BASEC/ICTRP)
  • Trial sites
    Bern, Zurich
    (BASEC)
  • Contact Prof. Dr. med. Matthias Guckenberger Matthias.Guckenberger@usz.ch (BASEC)
  • Data Source(s) BASEC: Import from 14.03.2025 ICTRP: N/A
  • Last update 14.03.2025 10:55

Summary description of the study

Since the 1990s, a radiation technique known as stereotactic body radiation therapy (SBRT) has been used for the local treatment of metastases, particularly in the brain, bones, lungs, liver, neck, lymph nodes, or other soft tissues. There are various ways to perform SBRT. In most cases, each metastasis is treated by administering a low radiation dose multiple times in succession, a technique referred to as SBRT with multiple fractions. Another technique involves administering a high radiation dose in a single session. Although this technique, known as SBRT with single fraction, may have several advantages (i.e., fewer hospital visits, less financial and logistical burden), it is still rarely used in clinical practice. In this sub-study, we investigate whether the administration of a high radiation dose in a single session (i.e., SBRT with single fraction) is as safe and effective for the treatment of oligometastases as the administration of several lower radiation doses (i.e., SBRT with multiple fractions).

(BASEC)

Intervention under investigation

We investigate whether the administration of a high radiation dose in a single session (i.e., SBRT with single fraction) is as safe and effective for the treatment of oligometastases as the administration of several lower radiation doses (i.e., SBRT with multiple fractions).

(BASEC)

Disease under investigation

oligometastatic tumor disease

(BASEC)

Criteria for participation in trial
oligometastatic tumor disease, a condition where cancer has spread from its original site to other parts of the body (new tumors referred to as oligometastases) (BASEC)

Exclusion criteria
None (BASEC)

Trial sites

Bern, Zurich

(BASEC)

not available

Sponsor

not available

Contact

Contact Person Switzerland

Prof. Dr. med. Matthias Guckenberger

+41442552930

Matthias.Guckenberger@usz.ch

(BASEC)

Scientific Information

not available

Name of the authorising ethics committee (for multicentre studies, only the lead committee)

Ethics Committee Zurich

(BASEC)

Date of authorisation

14.03.2025

(BASEC)


ICTRP Trial ID
not available

Official title (approved by ethics committee)
not available

Academic title
not available

Public title
not available

Disease under investigation
not available

Intervention under investigation
not available

Type of trial
not available

Trial design
not available

Inclusion/Exclusion criteria
not available

not available

Primary and secondary end points
not available

not available

Registration date
not available

Incorporation of the first participant
not available

Secondary sponsors
not available

Additional contacts
not available

Secondary trial IDs
not available

Results-Individual Participant Data (IPD)
not available

Further information on the trial
not available

Results of the trial

Results summary

not available

Link to the results in the primary register

not available